Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29527399 | 1.00 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL29768519 | 1.00 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL5789800 | 1.00 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL215068 | 1.00 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL6094926 | 0.89 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL215739 | 0.89 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL16893792 | 0.89 | PTGS2 (0.80) | PTGS2PTGS1 | |
| SCHEMBL16893789 | 0.89 | PTGS2 (0.80) | PTGS2PTGS1 | |
| SCHEMBL6092704 | 0.87 | PTGS2 (0.78) | PTGS2PTGS1 | |
| SCHEMBL6059769 | 0.87 | PTGS2 (0.78) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 703 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113330004-B | Differential solubility driven asymmetric conversion process for substituted 2H-chromene-3-carboxylic acids | 株式会社AskAt | 2023-11-17 | — | — | CN | claimed |
| US-20200383983-A1 | CGRP ANTAGONISTS FOR THE TREATMENT OF MEDICATION OVERUSE HEADACHE, POST-TRAUMATIC HEADACHE, POST-CONCUSSION SYNDROME AND VERTIGO | ALLERGAN SALES, LLC | 2020-12-10 | — | — | US | claimed |
| US-20170196835-A1 | COMBINATION OF A CHROMENE COMPOUND AND A SECOND ACTIVE AGENT | Euclises Pharmaceuticals, Inc. | 2017-07-13 | — | — | US | claimed |
| US-9447065-B2 | Pharmaceutical composition | RAQUALIA PHARMA INC. (JP) | 2016-09-20 | — | — | US | claimed |
| EP-2979695-A1 | THERAPEUTIC AGENT FOR EYE DISORDER | AskAt Inc. (JP) | 2016-02-03 | — | — | EP | claimed |
| US-20160008317-A1 | THERAPEUTIC AGENT FOR OCULAR DISEASE | ASKAT INC. (JP) | 2016-01-14 | — | — | US | claimed |
| US-20140256804-A1 | PHARMACEUTICAL COMPOSITION | RAQUALIA PHARMA INC. (JP) | 2014-09-11 | — | — | US | claimed |
| EP-2769718-A1 | MEDICINAL COMPOSITION | RaQualia Pharma Inc. (JP) | 2014-08-27 | — | — | EP | claimed |
| US-20130231311-A1 | NOVEL FORMULATIONS FOR TREATMENT OF MIGRAINE | ZOGENIX, INC. | 2013-09-05 | — | — | US | claimed |
| US-20110118189-A1 | NOVEL FORMULATIONS FOR TREATMENT OF MIGRAINE | ZOGENIX, INC. | 2011-05-19 | — | — | US | claimed |
| US-20020035264-A1 | Ophthalmic formulation of a selective cyclooxygenase-2 inhibitory drug | PHARMACIA & UPJOHN COMPANY | 2002-03-21 | — | — | US | claimed |
| WO-2002015884-A2 | RAPIDLY DISINTEGRATING ORAL FORMULATION OF A CYCLOOXYGENASE-2 INHIBITOR | PHARMACIA CORPORATION (US) | 2002-02-28 | — | — | WO | claimed |
| WO-2002015886-A2 | ORAL FAST-MELT DOSAGE FORM OF A CYCLOOXYGENASE-2 INHIBITOR | PHARMACIA CORPORATION (US) | 2002-02-28 | — | — | WO | claimed |
| US-20020015735-A1 | Sustained-release formulation of a cyclooxygenase-2 inhibitor | PHARMACIA CORPORATION | 2002-02-07 | — | — | US | claimed |
| US-20020009421-A1 | Therapy following skin injury from exposure to ultraviolet radiation | PHARMACIA CORPORATION | 2002-01-24 | — | — | US | claimed |
| WO-2001091856-A2 | USE OF COX2 INHIBITORS FOR TREATING SKIN INJURY FROM EXPOSURE TO ULTRAVIOLET RADIATION | PHARMACIA CORPORATION (US) | 2001-12-06 | — | — | WO | claimed |
| WO-2001045706-A1 | DUAL-RELEASE COMPOSITIONS OF A CYCLOOXYGENASE-2- INHIBITOR | PHARMACIA CORPORATION (US) | 2001-06-28 | — | — | WO | claimed |
| US-6034256-A | CYCLOOXYGEASE INHIBITOR | G.D. SEARLE & CO. (US) | 2000-03-07 | — | — | US | claimed |
| EP-0977748-A1 | SUBSTITUTED BENZOPYRAN DERIVATIVES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 2000-02-09 | — | — | EP | claimed |
| WO-1998047890-A1 | SUBSTITUTED BENZOPYRAN DERIVATIVES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1998-10-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256804-A1 | PHARMACEUTICAL COMPOSITION | CYP2C19, CYP2C9, CYP3A5 | PTGS2 36/4885PTGS1 40/4885 |
| US-20160008317-A1 | THERAPEUTIC AGENT FOR OCULAR DISEASE | ALDH1A2, PDE6C, PDE6A | PTGS2 692/4885PTGS1 272/4885 |
| US-20020009421-A1 | Therapy following skin injury from exposure to ultraviolet radiation | PTGS2, PTGES2, PTGS1 | PTGS2 1/4885PTGS1 3/4885 |
| US-20020035264-A1 | Ophthalmic formulation of a selective cyclooxygenase-2 inhibitory drug | PTGS2, PTGES2, PTGS1 | PTGS2 1/4885PTGS1 3/4885 |
| US-20020015735-A1 | Sustained-release formulation of a cyclooxygenase-2 inhibitor | PTGS2, PTGES2, PTGS1 | PTGS2 1/4885PTGS1 3/4885 |
| US-20170196835-A1 | COMBINATION OF A CHROMENE COMPOUND AND A SECOND ACTIVE AGENT | CD274, ICOS, PDCD1 | PTGS2 3149/4885PTGS1 2991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.